Literature DB >> 33961992

Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study).

Pedro María Martínez Pérez-Crespo1, Joaquín Felipe Lanz-García2, José Bravo-Ferrer2, María Luisa Cantón-Bulnes3, Adrian Sousa Domínguez4, Josune Goikoetxea Aguirre5, José María Reguera-Iglesias6, Eva León Jiménez7, Carlos Armiñanzas Castillo8, María Ángeles Mantecón Vallejo9, Teresa Marrodan Ciordia10, Jonathan Fernández Suárez11, Lucía Boix-Palop12, Jordi Cuquet Pedragosa13, Alfredo Jover Saenz14, Juan Sevilla Blanco15, Fátima Galán-Sánchez16, Clara Natera Kindelán17, Alfonso Del Arco Jiménez18, Alberto Bahamonde-Carrasco19, Alejandro Smithson Amat20, David Vinuesa García21, Carmen Herrero Rodríguez22, Isabel María Reche Molina23, Inés Pérez Camacho24, Antonio Sánchez-Porto25, Marcos Guzmán García26, Berta Becerril Carral27, Esperanza Merino de Lucas28, Inmaculada López-Hernández2, Jesús Rodríguez-Baño29, Luis Eduardo López-Cortés2.   

Abstract

The epidemiology of bloodstream infections (BSIs) is dynamic as it depends on microbiological, host and healthcare system factors. The aim of this study was to update the information regarding the epidemiology of BSIs in Spain considering the type of acquisition. An observational, prospective cohort study in 26 Spanish hospitals from October 2016 through March 2017 including all episodes of BSI in adults was performed. Bivariate analyses stratified by type of acquisition were performed. Multivariate analyses were performed by logistic regression. Overall, 6345 BSI episodes were included; 2510 (39.8%) were community-acquired (CA), 1661 (26.3%) were healthcare-associated (HCA) and 2056 (32.6%) hospital-acquired (HA). The 30-day mortality rates were 11.6%, 19.5% and 22.0%, respectively. The median age of patients was 71 years (interquartile range 60-81 years) and 3656 (58.3%; 95% confidence interval 57.1-59.6%) occurred in males. The proportions according to patient sex varied according to age strata. Escherichia coli (43.8%), Klebsiella spp. (8.9%), Staphylococcus aureus (8.9%) and coagulase-negative staphylococci (7.4%) were the most frequent pathogens. Multivariate analyses confirmed important differences between CA and HCA episodes, but also between HCA and HA episodes, in demographics, underlying conditions and aetiology. In conclusion, we have updated the epidemiological information regarding patients' profiles, underlying conditions, frequency of acquisition types and aetiological agents of BSI in Spain. HCA is confirmed as a distinct type of acquisition.
Copyright © 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Entities:  

Keywords:  Aetiology; Bacteraemia; Bloodstream infection; Epidemiology; Healthcare-associated

Year:  2021        PMID: 33961992     DOI: 10.1016/j.ijantimicag.2021.106352

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  1 in total

1.  Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort.

Authors:  Pedro María Martínez Pérez-Crespo; Álvaro Rojas; Joaquín Felipe Lanz-García; Pilar Retamar-Gentil; José María Reguera-Iglesias; Olalla Lima-Rodríguez; Alfonso Del Arco Jiménez; Jonathan Fernández Suárez; Alfredo Jover-Saenz; Josune Goikoetxea Aguirre; Eva León Jiménez; María Luisa Cantón-Bulnes; Pilar Ortega Lafont; Carlos Armiñanzas Castillo; Juan Sevilla Blanco; Jordi Cuquet Pedragosa; Lucía Boix-Palop; Berta Becerril Carral; Alberto Bahamonde-Carrasco; Teresa Marrodan Ciordia; Clara Natera Kindelán; Isabel María Reche Molina; Carmen Herrero Rodríguez; Inés Pérez Camacho; David Vinuesa García; Fátima Galán-Sánchez; Alejandro Smithson Amat; Esperanza Merino de Lucas; Antonio Sánchez-Porto; Marcos Guzmán García; Inmaculada López-Hernández; Jesús Rodríguez-Baño; Luis Eduardo López-Cortés
Journal:  Antibiotics (Basel)       Date:  2022-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.